DOCSLIB.ORG

Genome-Wide Approach to Identify Risk Factors for Therapy-Related Myeloid Leukemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genome-Wide Approach to Identify Risk Factors for Therapy-Related Myeloid Leukemia Leukemia (2006) 20, 239–246 & 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00 www.nature.com/leu ORIGINAL ARTICLE Genome-wide approach to identify risk factors for therapy-related myeloid leukemia A Bogni1, C Cheng2, W Liu2, W Yang1, J Pfeffer1, S Mukatira3, D French1, JR Downing4, C-H Pui4,5,6 and MV Relling1,6 1Department of Pharmaceutical Sciences, The University of Tennessee, Memphis, TN, USA; 2Department of Biostatistics, The University of Tennessee, Memphis, TN, USA; 3Hartwell Center, The University of Tennessee, Memphis, TN, USA; 4Department of Pathology, The University of Tennessee, Memphis, TN, USA; 5Department of Hematology/Oncology St Jude Children’s Research Hospital, The University of Tennessee, Memphis, TN, USA; and 6Colleges of Medicine and Pharmacy, The University of Tennessee, Memphis, TN, USA Using a target gene approach, only a few host genetic risk therapy increases, the importance of identifying host factors for factors for treatment-related myeloid leukemia (t-ML) have been secondary neoplasms increases. defined. Gene expression microarrays allow for a more 4 genome-wide approach to assess possible genetic risk factors Because DNA microarrays interrogate multiple ( 10 000) for t-ML. We assessed gene expression profiles (n ¼ 12 625 genes in one experiment, they allow for a ‘genome-wide’ probe sets) in diagnostic acute lymphoblastic leukemic cells assessment of genes that may predispose to leukemogenesis. from 228 children treated on protocols that included leukemo- DNA microarray analysis of gene expression has been used to genic agents such as etoposide, 13 of whom developed t-ML. identify distinct expression profiles that are characteristic of Expression of 68 probes, corresponding to 63 genes, was different leukemia subtypes.13,14 Studies using this method have significantly related to risk of t-ML. Hierarchical clustering of led to the identification of molecular events in the progression of these probe sets clustered patients into three groups with 94, 15–18 122 and 12 patients, respectively; 12 of the 13 patients who chronic myeloid leukemia (CML) and to the classification of 13,19 went on to develop t-ML were overrepresented in the latter AML and ALL subtypes. Microarray analysis has also been group (Po0.0001). A permutation test indicated a low likelihood used in childhood ALL to identify gene expression patterns at that these probe sets and clusters were obtained by chance diagnosis associated with risk of ALL relapse.13,20 (Po0.001). Distinguishing genes included transcription-related Variation in gene expression is likely to partly reflect variation oncogenes (v-Myb, Pax-5), cyclins (CCNG1, CCNG2 and in germline DNA. Gene expression in lymphoid tissue reflects CCND1) and histone HIST1H4C. Common transcription factor 21 recognition elements among similarly up- or downregulated inherited traits in cell lines from large kindreds. That gene genes included several involved in hematopoietic differentia- expression in ALL blasts differs by germline genetic polymorph- tion or leukemogenesis (Maz, PU.1, ARNT). This approach has isms,22 and can even predict which patients were likely to identified several genes whose expression distinguishes eventually develop a therapy-induced brain tumor,23 is also patients at risk of t-ML, and suggests targets for assessing consistent with the hypothesis that gene expression in ALL cells germline predisposition to leukemogenesis. Leukemia (2006) 20, 239–246. doi:10.1038/sj.leu.2404059; partially reflects germline characteristics, and not only the published online 8 December 2005 acquired genetic signature of the ALL subtype. In an initial Keywords: acute lymphoblastic leukemia; secondary myeloid analysis, gene expression profiles of diagnostic ALL cells were leukemia; gene expression also predictive of t-ML risk,13 but these data were analyzed in depth only among the largest molecularly defined ALL subgroup: those with Tel/AML1 translocations at diagnosis. Moreover, the time dependence of t-ML and competing risks for relapse were not considered. Background In this study, we used a genome-wide approach to identify genes whose expression discriminated patients with ALL who were predisposed to t-ML, using cumulative incidence and Cox A major unpredictable complication in the treatment of acute regression models for assessing the relationship between gene lymphoblastic leukemia (ALL) is treatment-related myeloid expression and time to t-ML. The two models identified 68 leukemia (t-ML), which includes treatment-related acute mye- common probe sets, corresponding to 63 genes, whose loid leukemia (AML) and myelodysplastic syndrome (MDS), 1,2 expression in ALL cells differed significantly between patients occurring in 1–10% of ALL patients. Characteristics of the ALL 3–9 who did versus those who did not develop t-ML. These results subtype do not appear to influence the risk of t-ML. Two suggest that pretreatment gene expression profiling can provide major types of t-ML have been reported: the form associated 3,5,6 insights into candidate genes involved as host factors in t-ML with the use of topoisomerase II inhibitors, with character- 10–12 development. istic balanced translocations of the MLL gene, and the form associated with alkylating agents7,8 associated with monosomy of chromosome 5 or 7.4 Although several treatment-related risk factors have been identified that interact with the primary Patients, materials and methods leukemogens, few host factors are known. As survival of cancer Patients and laboratory tests Correspondence: Professor MV Relling, Department of Pharmaceutical Protocols Total XIIIA (1991–1994) and Total XIIIB (1994–1998) Sciences, St Jude Children’s Research Hospital, 332 North Lauderdale, of St Jude Children’s Research Hospital were used for the Memphis, TN 38105-2794, USA. E-mail: [email protected] treatment of patients with newly diagnosed ALL. Both protocols Received 18 July 2005; revised 3 October 2005; accepted 31 October included the administration of topoisomerase II inhibitors and 2005; published online 8 December 2005 alkylating agents.24,25 The patient cohort herein consisted of all Gene expression and t-ML risk A Bogni et al 240 267 patients (228 with B-lineage and 39 with T-cell ALL) who set for t-ML, that risk can be so altered by that failure (or its were enrolled on the protocols and for whom gene expression attendant change in therapy) that it is improbable to observe a t- data from ALL cells at diagnosis were available. The median ML in such patients. In our particular study, no patient who length of follow-up was 6.1 years. In all, 14 patients developed developed t-ML experienced a competing adverse event before t-ML: 13 had B-lineage ALL and one patient had T-cell ALL as the t-ML. For this reason, we have also conducted a Cox the primary malignancy. The types of therapy-related leukemias regression model analysis, in which we censored patients with were AML (n ¼ 10), MDS (n ¼ 3), and CML (n ¼ 1). Herein, we relapse (or other failures) at the times of such events, and used restricted our analysis to those with B-lineage ALL for the survival models, instead of cumulative incidence models, for primary analysis (228 patients), but an identical analysis for all purposes of gene/probe set selection. Probe sets with Pp0.01 267 patients (those with T- or B-lineage ALL), is presented in the were considered as ‘statistically significant.’ Supplementary Information. Bone marrow blasts of ALL patients were cryopreserved on the date of diagnosis. Total RNA was extracted using Tri- Cluster analysis Reagent (MRC, Cincinnati, OH, USA). Patients, their parents, or Hierarchical clustering (Ward’s minimum-variance method) was guardians gave informed consent and assent to participate in the applied to cluster the patients into three groups, using the study. The protocols and the current analysis of risk factors were expression of probe sets selected by the above methods as approved by the Institutional Review Board of St Jude. RNA was features. As three major outcomes were present (no event, t-ML, submitted for microarray analysis as described.13 Labeled cRNA adverse events other then t-ML), the cluster tree was cut at the was hybridized to Affymetrix HG-U95Av2 GeneChips, which level that defined k ¼ 3 clusters. The cumulative incidence of t- comprise more than 12 600 probe sets for more than 9600 ML among the three clusters was compared using Gray’s test, unique genes. Gene expression was verified by a second using adverse events other than t-ML as competing risks.29 method in a subset (see Supplementary Information). Permutation test Statistical analysis To assess the probability that the discriminating probe sets could Gene expression data were extracted from Affymetrix-generated have been selected by chance, a permutation test was image files using MicroArray Suites (MAS) version 5.0. with performed separately for each group of selected probe sets default settings (Raw data available on http://www.stjudere- (using the methods described above). For these permutations, search.org/data/ALL1). The MAS 5.0-generated signal of each outcome was treated as a time-dependent event, allowing us to probe set was transformed by natural-log transformation (log ). e combine features of a ‘classification accuracy’ with a cumula- Statistical analysis was performed using SAS (SAS Inc., Cary, tive incidence comparison approach. In each of 1000 permuta- NC, USA), S-plus (Insightful, Seattle, WA, USA), StatXact 5 tions, the paired time-to-t-ML development and outcome event (Cytel, Cambridge, MA, USA) and R 1.6 (http://www.r-project. were randomly reassigned to each patient, and gene selection org/). For data visualization, principal component analysis (PCA) was performed by applying either the cumulative incidence and hierarchical clustering were performed using Spotfire regression or the Cox regression model to the permuted data. DecisionSite 7.0 (Spotfire, USA). The a value of 0.01 was the significance threshold, the same as All analyses were performed on the entire cohort (n ¼ 267) used on the original data.
Load more

Recommended publications
  • Deletion of the SNARE Vti1b in Mice Results in the Loss of a Single
    MOLECULAR AND CELLULAR BIOLOGY, Aug. 2003, p. 5198–5207 Vol. 23, No. 15 0270-7306/03/$08.00ϩ0 DOI: 10.1128/MCB.23.15.5198–5207.2003 Copyright © 2003, American Society for Microbiology. All Rights Reserved. Deletion of the SNARE vti1b in Mice Results in the Loss of Downloaded from a Single SNARE Partner, Syntaxin 8 Vadim Atlashkin,1 Vera Kreykenbohm,1 Eeva-Liisa Eskelinen,2 Dirk Wenzel,3 Afshin Fayyazi,4 and Gabriele Fischer von Mollard1* Zentrum Biochemie und Molekulare Zellbiologie, Abteilung Biochemie II,1 and Abteilung Pathologie,4 Universita¨t Go¨ttingen, and Abteilung Neurobiologie, Max-Planck Institut fu¨r Biophysikalische Chemie,3 Go¨ttingen, and http://mcb.asm.org/ Biochemisches Institut, Universita¨t Kiel, Kiel,2 Germany Received 13 February 2003/Accepted 26 April 2003 SNARE proteins participate in recognition and fusion of membranes. A SNARE complex consisting of vti1b, syntaxin 8, syntaxin 7, and endobrevin/VAMP-8 which is required for fusion of late endosomes in vitro has been identified recently. Here, we generated mice deficient in vti1b to study the function of this protein in vivo. vti1b-deficient mice had reduced amounts of syntaxin 8 due to degradation of the syntaxin 8 protein, while the amounts of syntaxin 7 and endobrevin did not change. These data indicate that vti1b is specifically required for the stability of a single SNARE partner. vti1b-deficient mice were viable and fertile. Most vti1b-deficient on February 22, 2016 by MAX PLANCK INSTITUT F BIOPHYSIKALISCHE CHEMIE mice were indistinguishable from wild-type mice and did not display defects in transport to the lysosome.
    [Show full text]
  • Functional Annotation of Exon Skipping Event in Human Pora Kim1,*,†, Mengyuan Yang1,†,Keyiya2, Weiling Zhao1 and Xiaobo Zhou1,3,4,*
    D896–D907 Nucleic Acids Research, 2020, Vol. 48, Database issue Published online 23 October 2019 doi: 10.1093/nar/gkz917 ExonSkipDB: functional annotation of exon skipping event in human Pora Kim1,*,†, Mengyuan Yang1,†,KeYiya2, Weiling Zhao1 and Xiaobo Zhou1,3,4,* 1School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA, 2College of Electronics and Information Engineering, Tongji University, Shanghai, China, 3McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA and 4School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA Received August 13, 2019; Revised September 21, 2019; Editorial Decision October 03, 2019; Accepted October 03, 2019 ABSTRACT been used as therapeutic targets (3–8). For example, MET has lost the binding site of E3 ubiquitin ligase CBL through Exon skipping (ES) is reported to be the most com- exon 14 skipping event (9), resulting in an enhanced expres- mon alternative splicing event due to loss of func- sion level of MET. MET amplification drives the prolifera- tional domains/sites or shifting of the open read- tion of tumor cells. Multiple tyrosine kinase inhibitors, such ing frame (ORF), leading to a variety of human dis- as crizotinib, cabozantinib and capmatinib, have been used eases and considered therapeutic targets. To date, to treat patients with MET exon 14 skipping (10). Another systematic and intensive annotations of ES events example is the dystrophin gene (DMD) in Duchenne mus- based on the skipped exon units in cancer and cular dystrophy (DMD), a progressive neuromuscular dis- normal tissues are not available.
    [Show full text]
  • Chromosomal Aberrations in Head and Neck Squamous Cell Carcinomas in Norwegian and Sudanese Populations by Array Comparative Genomic Hybridization
    825-843 12/9/08 15:31 Page 825 ONCOLOGY REPORTS 20: 825-843, 2008 825 Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization ERIC ROMAN1,2, LEONARDO A. MEZA-ZEPEDA3, STINE H. KRESSE3, OLA MYKLEBOST3,4, ENDRE N. VASSTRAND2 and SALAH O. IBRAHIM1,2 1Department of Biomedicine, Faculty of Medicine and Dentistry, University of Bergen, Jonas Lies vei 91; 2Department of Oral Sciences - Periodontology, Faculty of Medicine and Dentistry, University of Bergen, Årstadveien 17, 5009 Bergen; 3Department of Tumor Biology, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, 0310 Oslo; 4Department of Molecular Biosciences, University of Oslo, Blindernveien 31, 0371 Oslo, Norway Received January 30, 2008; Accepted April 29, 2008 DOI: 10.3892/or_00000080 Abstract. We used microarray-based comparative genomic logical parameters showed little correlation, suggesting an hybridization to explore genome-wide profiles of chromosomal occurrence of gains/losses regardless of ethnic differences and aberrations in 26 samples of head and neck cancers compared clinicopathological status between the patients from the two to their pair-wise normal controls. The samples were obtained countries. Our findings indicate the existence of common from Sudanese (n=11) and Norwegian (n=15) patients. The gene-specific amplifications/deletions in these tumors, findings were correlated with clinicopathological variables. regardless of the source of the samples or attributed We identified the amplification of 41 common chromosomal carcinogenic risk factors. regions (harboring 149 candidate genes) and the deletion of 22 (28 candidate genes). Predominant chromosomal alterations Introduction that were observed included high-level amplification at 1q21 (harboring the S100A gene family) and 11q22 (including Head and neck squamous cell carcinoma (HNSCC), including several MMP family members).
    [Show full text]
  • Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-Like Mouse Models: Tracking the Role of the Hairless Gene
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 5-2006 Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene Yutao Liu University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Life Sciences Commons Recommended Citation Liu, Yutao, "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino- like Mouse Models: Tracking the Role of the Hairless Gene. " PhD diss., University of Tennessee, 2006. https://trace.tennessee.edu/utk_graddiss/1824 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Yutao Liu entitled "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in Life Sciences. Brynn H. Voy, Major Professor We have read this dissertation and recommend its acceptance: Naima Moustaid-Moussa, Yisong Wang, Rogert Hettich Accepted for the Council: Carolyn R.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Function in Vertebrates Receptor-Containing Adaptor
    Evidence for Evolving Toll-IL-1 Receptor-Containing Adaptor Molecule Function in Vertebrates This information is current as Con Sullivan, John H. Postlethwait, Christopher R. Lage, of September 30, 2021. Paul J. Millard and Carol H. Kim J Immunol 2007; 178:4517-4527; ; doi: 10.4049/jimmunol.178.7.4517 http://www.jimmunol.org/content/178/7/4517 Downloaded from References This article cites 60 articles, 30 of which you can access for free at: http://www.jimmunol.org/content/178/7/4517.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 30, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Evidence for Evolving Toll-IL-1 Receptor-Containing Adaptor Molecule Function in Vertebrates1 Con Sullivan,* John H. Postlethwait,† Christopher R. Lage,* Paul J. Millard,‡ and Carol H. Kim2* In mammals, Toll-IL-1R-containing adaptor molecule 1 (TICAM1)-dependent TLR pathways induce NF-␬B and IFN-␤ re- sponses.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Human Retinoic Acid Signaling
    RT² Profiler PCR Array (96-Well Format and 384-Well [4 x 96] Format) Human Retinoic Acid Signaling Cat. no. 330231 PAHS-180Z For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 5700, 7000, 7300, 7500, Format A 7700, 7900HT, ViiA™ 7 (96-well block); Bio-Rad® models iCycler®, iQ™5, MyiQ™, MyiQ2; Bio-Rad/MJ Research Chromo4™; Eppendorf® Mastercycler® ep realplex models 2, 2s, 4, 4s; Stratagene® models Mx3005P®, Mx3000P®; Takara TP-800 RT² Profiler PCR Array, Applied Biosystems models 7500 (Fast block), 7900HT (Fast Format C block), StepOnePlus™, ViiA 7 (Fast block) RT² Profiler PCR Array, Bio-Rad CFX96™; Bio-Rad/MJ Research models DNA Format D Engine Opticon®, DNA Engine Opticon 2; Stratagene Mx4000® RT² Profiler PCR Array, Applied Biosystems models 7900HT (384-well block), ViiA 7 Format E (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (96-well block) Format F RT² Profiler PCR Array, Roche LightCycler 480 (384-well block) Format G RT² Profiler PCR Array, Fluidigm® BioMark™ Format H Sample & Assay Technologies Description The Human Retinoic Acid Pathway RT² Profiler PCR Array profiles the expression of 84 key genes involved in retinoic acid signaling. Retinoic acid (RA) is the primary functional derivative of vitamin A (retinol) and its activity is implicated in many aspects of vertebrate development and homeostasis, while disruptions in this pathway cause developmental abnormalities and disrupt function in adipose, cardiac, nervous, reproductive, and integumentary tissues, among others. RA acts primarily by binding a family of nuclear receptors (the retinoic acid receptors alpha, beta, and gamma) that then heterodimerize with their partners (the retinoid X receptors alpha, beta, and gamma) and alter transcription.
    [Show full text]
  • The Middle Temporal Gyrus Is Transcriptionally Altered in Patients with Alzheimer’S Disease
    1 The middle temporal gyrus is transcriptionally altered in patients with Alzheimer’s Disease. 2 1 3 Shahan Mamoor 1Thomas Jefferson School of Law 4 East Islip, NY 11730 [email protected] 5 6 We sought to understand, at the systems level and in an unbiased fashion, how gene 7 expression was most different in the brains of patients with Alzheimer’s Disease (AD) by mining published microarray datasets (1, 2). Comparing global gene expression profiles between 8 patient and control revealed that a set of 84 genes were expressed at significantly different levels in the middle temporal gyrus (MTG) of patients with Alzheimer’s Disease (1, 2). We used 9 computational analyses to classify these genes into known pathways and existing gene sets, 10 and to describe the major differences in the epigenetic marks at the genomic loci of these genes. While a portion of these genes is computationally cognizable as part of a set of genes 11 up-regulated in the brains of patients with AD (3), many other genes in the gene set identified here have not previously been studied in association with AD. Transcriptional repression, both 12 pre- and post-transcription appears to be affected; nearly 40% of these genes are transcriptional 13 targets of MicroRNA-19A/B (miR-19A/B), the zinc finger protein 10 (ZNF10), or of the AP-1 repressor jun dimerization protein 2 (JDP2). 14 15 16 17 18 19 20 21 22 23 24 25 26 Keywords: Alzheimer’s Disease, systems biology of Alzheimer’s Disease, differential gene 27 expression, middle temporal gyrus.
    [Show full text]
  • IGH Rearrangement in Myeloid Neoplasms Sion and Activation
    CASE REPORTS genes such as MYC and BCL2, leading to their overexpres- IGH rearrangement in myeloid neoplasms sion and activation. Here, we found two IGH rearrange- ments in myeloid tumors, including an IGH-MECOM in a Though immunoglobulin genes are typically expressed myelodysplastic syndrome (MDS) and an IGH-CCNG1 in in B lymphocytes, recent studies found ectopic an AML. Our studies provide the first evidence that a once immunoglobulin expression in non-B-cell tumor cells believed B-cell tumor-specific oncogenic mechanism is including acute myeloid leukemia (AML). The also present in myeloid tumors. immunoglobulin genes, including immunoglobulin heavy Case #1: A 60-year-old female with a history of breast chain genes (IGH), light kappa (k) chain genes (IGK) and cancer presented with fatigue, bilateral flank pain, and 9 light lambda (λ) chain genes (IGL), are frequently hematuria. Complete blood count showed 24.82x10 /L of rearranged in B-cell tumors. These rearrangements result white blood cells, 11.2 g/dL of hemoglobin, 33.9% of in a juxtaposition of IG enhancers to the vicinity of onco- hematocrit, and 68x109/L of platelets. The bone marrow A B C D E Figure 1. Acute myeloid leukemia with an IGH-CCNG1 rearrangement. (A) Chromosome analysis of the bone marrow aspirate showed a complex karyotype, including an unbalanced translocation involving chromosomes 5, 14 and 19. Arrows indicate clonal aberrations. (B) Fluorescence in situ hybridization (FISH) on abnormal metaphase showed the 3'IGH (red) remaining on the derivative chromosome 14 and the 5'IGH lost, consistent with an unbalanced IGH rearrange- ment.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • A Yeast Phenomic Model for the Influence of Warburg Metabolism on Genetic Buffering of Doxorubicin Sean M
    Santos and Hartman Cancer & Metabolism (2019) 7:9 https://doi.org/10.1186/s40170-019-0201-3 RESEARCH Open Access A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin Sean M. Santos and John L. Hartman IV* Abstract Background: The influence of the Warburg phenomenon on chemotherapy response is unknown. Saccharomyces cerevisiae mimics the Warburg effect, repressing respiration in the presence of adequate glucose. Yeast phenomic experiments were conducted to assess potential influences of Warburg metabolism on gene-drug interaction underlying the cellular response to doxorubicin. Homologous genes from yeast phenomic and cancer pharmacogenomics data were analyzed to infer evolutionary conservation of gene-drug interaction and predict therapeutic relevance. Methods: Cell proliferation phenotypes (CPPs) of the yeast gene knockout/knockdown library were measured by quantitative high-throughput cell array phenotyping (Q-HTCP), treating with escalating doxorubicin concentrations under conditions of respiratory or glycolytic metabolism. Doxorubicin-gene interaction was quantified by departure of CPPs observed for the doxorubicin-treated mutant strain from that expected based on an interaction model. Recursive expectation-maximization clustering (REMc) and Gene Ontology (GO)-based analyses of interactions identified functional biological modules that differentially buffer or promote doxorubicin cytotoxicity with respect to Warburg metabolism. Yeast phenomic and cancer pharmacogenomics data were integrated to predict differential gene expression causally influencing doxorubicin anti-tumor efficacy. Results: Yeast compromised for genes functioning in chromatin organization, and several other cellular processes are more resistant to doxorubicin under glycolytic conditions. Thus, the Warburg transition appears to alleviate requirements for cellular functions that buffer doxorubicin cytotoxicity in a respiratory context.
    [Show full text]